BetterLife Pharma (BETRF) Short term Debt (2011 - 2026)

BetterLife Pharma's Short term Debt history runs 16 years deep, the most recent figure standing at $1.2 million for Q2 2026.

• In Q2 2026, Short term Debt rose 100.48% year-over-year to $1.2 million; the TTM figure through Apr 2026 stood at $1.2 million (up 100.48% YoY), while the FY2026 annual figure was $1.0 million, changed N/A from the prior year.
• Short term Debt for Q2 2026 stood at $1.2 million, up from $1.0 million in the prior quarter.
• The five-year high for Short term Debt was $5.2 million in Q1 2023, with the low at $114456.8 in Q1 2022.
• The 5-year median for Short term Debt is $665865.4 (2024), against an average of $1.2 million.
• The sharpest annual moves came in 2022 and 2023: Short term Debt slumped 77.75% in 2022, then soared 4481.28% in 2023.
• BetterLife Pharma's Short term Debt stood at $554073.8 in 2022, then rose by 27.7% to $707545.0 in 2023, then increased by 15.85% to $819657.3 in 2024, then dropped by 16.24% to $686517.0 in 2025, then soared by 67.76% to $1.2 million in 2026.
• Business Quant data shows BETRF's Short term Debt at $1.2 million in Q2 2026, $1.0 million in Q1 2026, and $686517.0 in Q3 2025.